The Supreme Court restored mail ordering of mifepristone, reversing a federal appeals court’s stay that had blocked the access.
Mifepristone is an FDA-approved abortion medication, and its mail-order access has been the subject of ongoing federal litigation. The appeals court’s stay shut down that channel. Monday’s ruling reopens it.
The important distinction: the Supreme Court reversed a stay, not a final ruling on the merits. A stay is a temporary pause issued while litigation plays out in the courts. Whatever case generated the appeals court’s stay is still active, and Monday’s ruling doesn’t resolve it.
The what-if is real: when the underlying case reaches a final disposition, the mail-order question must be answered again, and this time there won’t be a stay reversal available as the interim fix. If that ruling goes against mail-order access, Monday’s restoration becomes a footnote.
The legal fight over mifepristone’s availability isn’t over. Monday changed the interim scoreboard.
— Sarah Chen